Los Angeles, CA -- (SBWIRE) -- 04/11/2019 -- Gabapentin is a medication used to treat epilepsy, neuropathic pain, hot flashes, and restless legs syndrome. In epilepsy, it may be used for those with partial seizures. It is recommended as one of a number of first line medications for the treatment of neuropathic pain in diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain.
Gabapentin was originally marketed under the brand name Neurontin and since it became generic, it has been marketed under many other brand names. An extended-release formulation of gabapentin for once-daily administration was introduced in 2011 for postherpetic neuralgia under the brand name Gralise.
Gabapentin is used primarily to treat seizures and neuropathic pain. It is also commonly prescribed for many off-label uses, such as treatment of anxiety disorders, insomnia, and bipolar disorder. There are, however, concerns regarding the quality of the trials conducted and evidence for some such uses, especially in the case of its use as a mood stabilizer in bipolar disorder.
The global Gabapentin market was 1430 million US$ in 2018 and is expected to 1630 million US$ by the end of 2025, growing at a CAGR of 1.8% between 2019 and 2025.
Get PDF template of this report: https://www.qyresearch.com/sample-form/form/1076214/global-gabapentin-market
This report studies the Gabapentin market size (value and volume) by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Gabapentin in these regions, from 2014 to 2025, covering
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia and Turkey etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil etc.)
Middle East and Africa (Egypt and GCC Countries)
The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market include
By the product type, the market is primarily split into
By the end users/application, this report covers the following segments
Restless Legs Syndrome
We can also provide the customized separate regional or country-level reports, for the following regions:
Rest of Asia-Pacific
Rest of Europe
Central & South America
Rest of Central & South America
Middle East & Africa
Rest of Middle East & Africa
Get Full Report Now at USD 3,550 @ https://www.qyresearch.com/settlement/pre/6d398e40a883712f692144ca64d02d06,0,1,Global%20Gabapentin%20Market%20Report,%20History%20and%20Forecast%202014-2025,%20Breakdown%20Data%20by%20Manufacturers,%20Key%20Regions,%20Types%20and%20Application
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in the consulting industry.